Vinva Investment Management Ltd Boosts Stock Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Vinva Investment Management Ltd lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 130.2% in the third quarter, HoldingsChannel.com reports. The firm owned 38,540 shares of the company’s stock after purchasing an additional 21,795 shares during the period. Vinva Investment Management Ltd’s holdings in Neurocrine Biosciences were worth $4,434,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth about $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth about $30,000. EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences in the second quarter worth about $35,000. Plato Investment Management Ltd purchased a new stake in Neurocrine Biosciences in the first quarter worth about $41,000. Finally, Blue Trust Inc. lifted its holdings in Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after buying an additional 220 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Trading Down 1.0 %

NASDAQ:NBIX opened at $126.59 on Friday. Neurocrine Biosciences, Inc. has a 12 month low of $110.81 and a 12 month high of $157.98. The company has a market cap of $12.82 billion, a PE ratio of 33.94 and a beta of 0.35. The company has a 50 day simple moving average of $119.09 and a two-hundred day simple moving average of $131.67.

Analysts Set New Price Targets

Several analysts have commented on NBIX shares. HC Wainwright restated a “buy” rating and issued a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Oppenheimer raised their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Barclays lowered their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating for the company in a report on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research note on Monday, September 16th. Finally, Piper Sandler raised shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and raised their target price for the company from $131.00 to $159.00 in a research note on Thursday, August 29th. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.